Understanding the Mechanism of Action of Crovalimab
•
3 min read
Crovalimab is a novel anti-C5 monoclonal antibody approved to treat paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disorder characterized by complement-mediated red blood cell destruction. Its mechanism of action involves a unique recycling technology that enhances its efficiency and allows for convenient subcutaneous dosing every four weeks.
